drugset / Trial / NCT04806243
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
Phase 2
Unknown
69 enrolled
Nanfang Hospital, Southern Medical University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Regorafenib | Small molecule | 80 mg | — |